AI Clinical Trial Endpoint Tool Gains Regulatory Approval
zakkohane · x · 2026-07-19
A new Perspective article discusses the significance of an AI-enabled clinical trial endpoint tool (AIM-NASH) receiving recognition from the European Medicines Agency and the US FDA.
The accompanying image lists various potential AI applications in clinical trial endpoints, including:
- Pathology, imaging, physiological imaging as surrogate endpoints
- Symptom reports, functional assessments, event classification as clinical endpoints
- Using sensors, smartphones, and AI classification models to improve data collection and endpoint adjudication consistency
The article focuses not on a single model, but on how such tools change clinical evidence generation and endpoint adjudication processes.
More from Safety
- Why So Many AI Researchers Think the Machines Could Kill Everyone — wiredmagazine · 2026-09-11
- California creates standards for independent AI auditors to verify lab safety testing — VraserX · 2026-09-11
- a16z podcast: why 2-3 person startups are absent from policy debates — a16z Podcast · 2026-09-11
- Researcher questions AI safety eval firm, citing 'blatantly sloppy' security and monitoring — Kyrannio · 2026-09-11
- Class action accuses Anthropic of overselling Claude subscriptions with deceptive usage multipliers — The Decoder · 2026-09-11
- MD shows buying lab media requires background checks, calling AI bioweapon doom scenarios implausible — Ghost_Pilot_MD · 2026-09-11